Ovid Therapeutics Statistics
Total Valuation
OVID has a market cap or net worth of $423.94 million. The enterprise value is $271.41 million.
Important Dates
The last earnings date was Tuesday, May 12, 2026, before market open.
| Earnings Date | May 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
OVID has 173.04 million shares outstanding. The number of shares has increased by 26.81% in one year.
| Current Share Class | 173.04M |
| Shares Outstanding | 173.04M |
| Shares Change (YoY) | +26.81% |
| Shares Change (QoQ) | +66.73% |
| Owned by Insiders (%) | 2.35% |
| Owned by Institutions (%) | 55.50% |
| Float | 138.84M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 59.53 |
| Forward PS | n/a |
| PB Ratio | 2.07 |
| P/TBV Ratio | 2.14 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 38.11 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 10.17, with a Debt / Equity ratio of 0.07.
| Current Ratio | 10.17 |
| Quick Ratio | 9.88 |
| Debt / Equity | 0.07 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -18.77% and return on invested capital (ROIC) is -73.29%.
| Return on Equity (ROE) | -18.77% |
| Return on Assets (ROA) | -19.42% |
| Return on Invested Capital (ROIC) | -73.29% |
| Return on Capital Employed (ROCE) | -22.74% |
| Weighted Average Cost of Capital (WACC) | 5.11% |
| Revenue Per Employee | $309,652 |
| Profits Per Employee | -$1.04M |
| Employee Count | 23 |
| Asset Turnover | 0.05 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +758.75% in the last 52 weeks. The beta is 0.19, so OVID's price volatility has been lower than the market average.
| Beta (5Y) | 0.19 |
| 52-Week Price Change | +758.75% |
| 50-Day Moving Average | 2.58 |
| 200-Day Moving Average | 1.76 |
| Relative Strength Index (RSI) | 41.56 |
| Average Volume (20 Days) | 1,778,581 |
Short Selling Information
The latest short interest is 8.53 million, so 4.93% of the outstanding shares have been sold short.
| Short Interest | 8.53M |
| Short Previous Month | 6.96M |
| Short % of Shares Out | 4.93% |
| Short % of Float | 6.14% |
| Short Ratio (days to cover) | 2.87 |
Income Statement
In the last 12 months, OVID had revenue of $7.12 million and -$23.90 million in losses. Loss per share was -$0.27.
| Revenue | 7.12M |
| Gross Profit | 7.12M |
| Operating Income | -47.74M |
| Pretax Income | -24.17M |
| Net Income | -23.90M |
| EBITDA | -47.57M |
| EBIT | -47.74M |
| Loss Per Share | -$0.27 |
Full Income Statement Balance Sheet
The company has $155.52 million in cash and $13.07 million in debt, with a net cash position of $152.53 million or $0.88 per share.
| Cash & Cash Equivalents | 155.52M |
| Total Debt | 13.07M |
| Net Cash | 152.53M |
| Net Cash Per Share | $0.88 |
| Equity (Book Value) | 198.27M |
| Book Value Per Share | 1.19 |
| Working Capital | 144.40M |
Full Balance Sheet Cash Flow
| Operating Cash Flow | -41.95M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 167,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -41.95M |
| FCF Per Share | -$0.24 |
Full Cash Flow Statement Margins
| Gross Margin | 100.00% |
| Operating Margin | -670.25% |
| Pretax Margin | -339.33% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
OVID does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -26.81% |
| Shareholder Yield | -26.81% |
| Earnings Yield | -5.64% |
| FCF Yield | -9.90% |
Analyst Forecast
The average price target for OVID is $5.47, which is 123.27% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $5.47 |
| Price Target Difference | 123.27% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 10 |
| Revenue Growth Forecast (5Y) | 80.27% |
| EPS Growth Forecast (5Y) | n/a |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |